-
公开(公告)号：US09328387B2
公开(公告)日：2016-05-03
申请号：US12675598
申请日：2008-09-10
CPC分类号： C12Q1/6883 , A61K31/454 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
-
2.发明授权Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms 有权伊立替尼治疗精神病症状的有效性的遗传标记公开(公告)号：US09080214B2
公开(公告)日：2015-07-14
申请号：US12600036
申请日：2008-05-17
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
摘要： Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.
摘要翻译： 描述了基于个体在一个或多个单核苷酸多态性（SNP）基因座上的基因型是否依据碘吡啶酮治疗个体精神病症状有效的方法，以及基于这种预测治疗个体的方法。
-
3.发明申请GENETIC MARKERS FOR EFFICACY OF ILOPERIDONE IN THE TREATMENT OF PSYCHOTIC SYMPTOMS 有权ILOPERIDONE治疗心理症状的基因标记公开(公告)号：US20110021566A1
公开(公告)日：2011-01-27
申请号：US12600036
申请日：2008-05-17
IPC分类号： A61K31/445 , G06F19/00
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
摘要： Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.
摘要翻译： 描述了基于个体在一个或多个单核苷酸多态性（SNP）基因座上的基因型是否依据碘吡啶酮治疗个体精神病症状有效的方法，以及基于这种预测治疗个体的方法。
-
公开(公告)号：US20110118313A1
公开(公告)日：2011-05-19
申请号：US12991766
申请日：2009-05-15
IPC分类号： A61K31/4535 , C12Q1/68 , C40B30/00 , A61K31/138 , A61P25/00 , A61P25/18
CPC分类号： A61K31/00 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/5023 , G01N33/5058 , G01N33/6896 , G01N33/92 , G01N2500/10 , G01N2800/302 , G01N2800/52
摘要： Molecular signature for antipsychotics and SERMs has been identified, namely their upregulation of genes that alter lipid homeostasis, preferably of one or more of the following genes: TNSIG1, SCD, FADS2, LDLR, FDPS, ACAT2, FDFT1, CYP51A1, FASN, DHCR7, RAB26, TM7SF2, SATB1, FAM117, GPNMB, NUPR1, VAC14, and LSS.
摘要翻译： 已经鉴定了抗精神病药和SERMs的分子特征，即其改变脂质体内平衡的基因的上调，优选一种或多种以下基因：TNSIG1，SCD，FADS2，LDLR，FDPS，ACAT2，FDFT1，CYP51A1，FASN，DHCR7， RAB26，TM7SF2，SATB1，FAM117，GPNMB，NUPR1，VAC14和LSS。
-
公开(公告)号：US08652776B2
公开(公告)日：2014-02-18
申请号：US12675607
申请日：2008-09-10
申请人： Christian Lavedan , Simona Volpi , Louis Licamele , Kendra Tomino Mack , Callie Michelle Heaton
发明人： Christian Lavedan , Simona Volpi , Louis Licamele , Kendra Tomino Mack , Callie Michelle Heaton
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
摘要翻译： 本发明涉及在基于一个或多个单核苷酸多态性（SNP）基因座上个体的基因型和基于这种预测的患者治疗后，能够增加个体的QT间期的化合物的给药后的QT延长的预测。
-
公开(公告)号：US09074255B2
公开(公告)日：2015-07-07
申请号：US13263075
申请日：2010-04-05
申请人： Christian Lavedan , Simona Volpi , Louis Licamele
发明人： Christian Lavedan , Simona Volpi , Louis Licamele
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C07D413/04 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156
摘要： The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
摘要翻译： 本发明描述了FAM13A1（具有序列相似性13，成员A1）家族的家族和QT间期延长的倾向之间的遗传多态性之间的关联，并且提供了用于预测这种倾向的相关方法，QT间期的施用 - 将化合物延长至具有这种倾向的个体，并确定化合物是否能够诱导QT延长。
-
公开(公告)号：US09072742B2
公开(公告)日：2015-07-07
申请号：US13263077
申请日：2010-04-05
申请人： Christian Lavedan , Simona Volpi , Louis Licamele
发明人： Christian Lavedan , Simona Volpi , Louis Licamele
IPC分类号： C12Q1/68 , A61K31/519
CPC分类号： C12Q1/6883 , A61K31/519 , C07D413/04 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156
摘要： The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
摘要翻译： 本发明描述了BAI3基因的遗传多态性与延长QT间期的倾向之间的关联，并提供了预测这种倾向的相关方法，对具有这种倾向的个体施用QT间期延长化合物， 并确定化合物是否能够诱导QT延长。
-
公开(公告)号：US20120058201A1
公开(公告)日：2012-03-08
申请号：US13263075
申请日：2010-04-05
申请人： Christian Lavedan , Simona Volpi , Louis Licamele
发明人： Christian Lavedan , Simona Volpi , Louis Licamele
IPC分类号： A61K33/36 , A61K31/45 , A61K31/517 , A61K31/4706 , A61K31/7048 , C12Q1/68 , A61P9/00 , A61K31/343 , A61K31/40 , A61K31/5415 , A61K31/4402 , A61K31/454 , A61K31/5383
CPC分类号： C12Q1/6883 , C07D413/04 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156
摘要： The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
摘要翻译： 本发明描述了FAM13A1（具有序列相似性13，成员A1）家族的家族和QT间期延长的倾向之间的遗传多态性之间的关联，并且提供了用于预测这种倾向的相关方法，QT间期的施用 - 将化合物延长至具有这种倾向的个体，并确定化合物是否能够诱导QT延长。
-
公开(公告)号：US20100249188A1
公开(公告)日：2010-09-30
申请号：US12675607
申请日：2008-09-10
申请人： Christian Lavedan , Simona Volpi , Louis Licamele , Kendra Tomino Mack , Callie Michelle Heaton
发明人： Christian Lavedan , Simona Volpi , Louis Licamele , Kendra Tomino Mack , Callie Michelle Heaton
IPC分类号： A61K31/454 , C12Q1/68 , A61K31/5517 , A61K31/519 , A61K31/554 , A61K31/407 , A61K31/496 , A61K31/38 , A61K31/40 , A61K31/452 , A61P25/18
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
摘要翻译： 本发明涉及在基于一个或多个单核苷酸多态性（SNP）基因座上个体的基因型和基于这种预测的患者治疗后，能够增加个体的QT间期的化合物的给药后的QT延长的预测。
-
公开(公告)号：US09074256B2
公开(公告)日：2015-07-07
申请号：US13263076
申请日：2010-04-05
申请人： Christian Lavedan , Simona Volpi , Louis Licamele
发明人： Christian Lavedan , Simona Volpi , Louis Licamele
IPC分类号： C12Q1/68 , A61K31/519
CPC分类号： C12Q1/6883 , A61K31/519 , C07D413/04 , C12Q2600/106 , C12Q2600/156
摘要： The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
摘要翻译： 本发明描述了ABCC2基因的遗传多态性与延长QT间期的倾向之间的关联，并且提供了预测这种倾向的相关方法，向具有这种倾向的个体施用QT间期延长化合物， 并确定化合物是否能够诱导QT延长。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.02 秒)
